Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc. is a NASDAQ-listed common stock issue representing the equity of a biopharmaceutical company focused on rare kidney and metabolic diseases in the United States. The company markets FILSPARI (sparsentan), an oral therapy designed to act on two pathways involved in the progression of IgA nephropathy, and Thiola and Thiola EC (tiopronin tablets), which are used to treat cystinuria, a rare genetic disorder associated with elevated cystine levels in urine and recurrent kidney stones. Travere also has clinical-stage programs that include sparsentan, being studied for focal segmental glomerulosclerosis, and pegtibatinase, an investigational enzyme replacement candidate for classical homocystinuria. In addition, the company has a collaboration with PharmaKrysto Limited related to pre-clinical work in its cystinuria program. Travere Therapeutics is headquartered in San Diego, California, and was formerly known as Retrophin, Inc. before adopting its current name in November 2020.

Jump directly to the stock analysis sections supported by the latest available data.